There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Globus Medical (GMED – Research Report) and Abivax SA Sponsored ADR (ABVX – Research Report) with bullish sentiments.
Globus Medical (GMED)
In a report released today, Matthew O’Brien from Piper Sandler upgraded Globus Medical to Buy, with a price target of $80.00. The company’s shares closed last Friday at $64.40, close to its 52-week high of $65.74.
According to TipRanks.com, O’Brien is a 4-star analyst with an average return of
Currently, the analyst consensus on Globus Medical is a Moderate Buy with an average price target of $69.20, an 8.3% upside from current levels. In a report issued on May 7, Canaccord Genuity also maintained a Buy rating on the stock with a $79.00 price target.
See today’s best-performing stocks on TipRanks >>
Abivax SA Sponsored ADR (ABVX)
Abivax SA Sponsored ADR received a Buy rating and a $43.00 price target from BTIG analyst Julian Harrison today. The company’s shares closed last Friday at $13.64.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Abivax SA Sponsored ADR with a $36.71 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GMED:
